108. SureScripts. Scripts Network Alliance: 2021 national progress report. 2022; https://surescripts.com/docs/ default-source/national-progress-reports/2021-national- progress-report.pdf?sfvrsn=71fcbe15_14 109. National Conference of State Legislatures (NCSL). Prescribing policies: States confront opioid overdose epidemic. 2019; https://www.ncsl.org/research/health/ prescribing-policies-states-confront-opioid-overdose- epidemic.aspx 110. U.S. Drug Enforcement Agency (DEA). Drugs of abuse: A DEA resource guide. https://www.dea.gov/sites/default/ files/2020-04/Drugs%20of%20Abuse%202020- Web%20Version-508%20compliant-4-24-20_0.pdf 111. Alternatives to Opiates (ALTOSM) Program. Accessed April 1, 2023; https://stjosephsalto.org/about. 112. Moradi MM, Moradi MM, Safaie A, Baratloo A, Payandemehr P. Sub dissociative dose of ketamine with haloperidol versus fentanyl on pain reduction in patients with acute pain in the emergency department; a randomized clinical trial. Am J Emerg Med. 2022 Apr;54:165-171. doi: 10.1016/j.ajem.2022.02.012; PMID: 35152127 113. Levine DA. “Pharming”: the abuse of prescription and over-the-counter drugs in teens. Current opinion in pediatrics. 2007;19(3):270-274. 114. Food and Drug Administration. Disposal of unused medicines: what you should know. Accessed April 15, 2023; https://www.fda.gov/drugs/safe-disposal- medicines/disposal-unused-medicines-what-you-should- know 115. U.S. Food and Drug Administration (FDA). FDA education blueprint for health care providers involved in treating and monitoring patients with pain. 2018 116. U.S. Food and Drug Administration (FDA). FDA warns about several safety issues with opioid pain medicines; requires label changes. Accessed April 9, 2023; https:// www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug- safety-podcast-fda-warns-about-several-safety-issues- opioid-pain-medicines-requires-label 117. U.S. Food and Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS). Accessed April 16, 2021; https://www.accessdata.fda. gov/scripts/cder/rems/index.cfm?event=RemsDetails. page&REMS=17 118. SureScripts. Scripts Network Alliance: 2021 national progress report. Accessed April 17, 2023; https:// surescripts.com/docs/default-source/national- progress-reports/2021-national-progress-report. pdf?sfvrsn=71fcbe15_14 119. Tori ME, Larochelle MR, Naimi TS. Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States. JAMA Network Open, 3 (4), e202361.2020; doi: 10.1001/jamanetworkopen.2020.2361 120. U.S. Food and Drug Administration (FDA). FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. 2022; https://www.fda.gov/drugs/fda-drug-safety-podcasts/ fda-drug-safety-podcast-fda-urges-caution-about- withholding-opioid-addiction-medications-patients 121. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet . 2020 Jun 20;395(10241):1938-1948. 122. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med . 2000 Oct-Nov;67(5-6):347-64. PMID: 11064485 123. NIDA. Preface. August 3. Accessed April 24, 2023; https:// nida.nih.gov/publications/principles-drug-addiction- treatment-research-based-guide-third-edition/preface 124. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. Obstet Gynecol. 2017;130:e81–94. 125. https://www.deadiversion.usdoj.gov/pubs/docs/MATE_ Training_Letter_Final.pdf 126. Samhsa.gov/medications-substance-use-disorders/ removal-data-waiver-requirement, Accessed April 28,2023 127. Singh D, Saadabadi A. Naltrexone. StatPearls. 2022.
128. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O’Brien CP SON. Extended- release naltrexone to prevent opioid relapse in criminal justice offenders. Engl J Med. 2016;374(13):1232. 129. National Institutes of Health, HEAL Initiative®. Accessed April 11, 2023. https://heal.nih.gov/about 130. Council of State and Territorial Epidemiologists. Healthcare associated infections, drug diversion planning and response toolkit for state and local health departments, Accessed April 17, 2023, https://cdn.ymaws.com/www. cste.org/resource/resmgr/pdfs/pdfs2/Drug_Diversion_ Toolkit_LiveL.pdf 131. Maharjan S, Amjad Z, Abaza A, et al. Executive dysfunction in patients with alcohol use disorder: a systematic review. Cureus . 2022;14(9):e29207. doi: 10.7759/ cureus.29207 132. Federation of State Medical Boards. Policy on physician illness and impairment: towards a model that optimizes patient safety and physician health. Accessed April 28, 2023, https://www.fsmb.org/siteassets/advocacy/ policies/policy-on-physician-impairment.pdf 133. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593. 134. Merlo, L, Teitelbaum. Substance use disorders in physicians: Epidemiology, clinical manifestations, identification, and engagement. UpToDate . Accessed April 28, 2023. journalofethics.2015.17.10.spec1-1510 136. Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley 135. AMA J Ethics. 2015;888-893. doi: 10.1001/ A, Wood E, Fairbairn N. (2020). Treatment of stimulant use disorder: A systematic review of reviews. PloS One, 15(6), e0234809. https://doi.org/10.1371/journal. pone.0234809 137. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. J AMA Psychiatry 2013; 70:1338. 138. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med . 2021;384(2):140-153. doi: 10.1056/ NEJMoa2020214 139. Shepherd RT. Mechanism of sudden death associated with volatile substance abuse. Hum Toxicol . 1989;8(4):287- 291. doi: 10.1177/096032718900800406 140. Perry, H. Inhalant misuse in children and adolescents In: Burns M, Ganetsky M, eds. UpToDate . 2023. Accessed May 10, 2023 https://www.uptodate.com 141. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med . 2008;35(2):158-176. doi: 10.1016/j.amepre.2008.04.009 142. Pack QR, Priya A, Lagu TC, et al. Short-term safety of nicotine replacement in smokers hospitalized with coronary heart disease. J Am Heart Assoc . 2018;7(18):e009424. doi: 10.1161/JAHA.118.009424 143. Wadgave U, Nagesh L. Nicotine replacement therapy: an overview. Int J Health Sci (Qassim) . 2016;10(3):425-435. 144. Sindelar JL. Regulating vaping—policies, possibilities, and perils. N Engl J Med . 2020;382(20):e54. doi: 10.1056/ NEJMp1917065 145. Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med . 2015;88(3):247-256. 146. Hage R, Schuurmans MM. Suggested management of e-cigarette or vaping product use associated lung injury (EVALI). J Thorac Dis . 2020;12(7):3460-3468. doi: 10.21037/jtd.2020.03.101
148
Powered by FlippingBook